Navigation Links
CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
Date:2/7/2008

r certain heart defects, CryoValve SG may give these kids a great opportunity to live active, normal lives. As a surgeon, I'm very excited to be able to offer them and their families this treatment option."

At FDA's request, CryoLife is planning a post-clearance study to seek evidence for the potential and implied long-term benefits of the SynerGraft process. Data to be collected is expected to include long-term safety and hemodynamic function, immune response, and explant analysis. CryoLife believes that this information may help it ascertain whether the SynerGraft process reduces the immunogenicity of the transplanted heart valve and recellularizes with the recipients own cells.

CryoLife will be using the SynerGraft technology for the majority of its pulmonary valve processing and anticipates that the first CryoValve SG may be available for shipment late in the first quarter of 2008.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding anticipated effectiveness, benefits and indications for use of CryoValve SG as well as the timing of use of the SynerGraft technology. These
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CryoLife Names Philip Theodore as Vice President, General Counsel
2. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
3. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
4. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
5. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
6. CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York
7. CryoLife to Present at OneMedPlace Finance Forum
8. CryoLife Announces Record Preservation Services and Product Revenues for 2007
9. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
10. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
11. CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured ... against Genewiz Inc. in excess of $10 million. The ... trade secrets, and that it improperly hired one or ... order denying motions for judgment notwithstanding the verdict, a ...
(Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN now ... Length Gauge offerings with new variants of its successful ... HEIDENHAIN’s pencil probe-style SPECTO length gauge series now offers ... 1Vpp, 12mm stroke length variants of the SPECTO series ... variant with a weak spring, 0.4N of gauging force, ...
(Date:2/26/2015)... February 26, 2015 Regis Technologies ... development of oncology drug substances. , Regis Technologies is ... their new Potent Compound Suite (PCS) for 2015. , ... square foot, cGMP facility in Morton Grove, Illinois. The ... of potent compounds up to about one kilogram per ...
(Date:2/26/2015)... PHILADELPHIA , Feb. 26, 2015  Spark Therapeutics (NASDAQ: ... its management team will participate in the Cowen and ... at 9:40 a.m., Eastern, at the Boston Marriott Copley ... a Spark Therapeutics presentation from the Cowen conference, please ... Events" section of the Spark Therapeutics website at ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Regis Extends cGMP Services to Oncology Market 2Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2
... ionized gas to carve tiny components on silicon wafers) ... the observation that the number of transistors that can ... two years. Without the compensating capabilities of plasma etching, ... sizes at about 1 micron (the diameter of a ...
... /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. ... outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, ... its financial results for the third quarter of 2011. ... Increased 24.0% Year Over Year to $104.0 Million ...
... Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm (the "Company") ... (HIV) infections, today announced its financial results for the ... reported a net loss of $375,852 ($0.02 per share) ... to $644,666 ($0.04 per share) for the same period ...
Cached Biology Technology:Plasma etching pushes the limits of a shrinking world 2WuXi PharmaTech Announces Third-Quarter 2011 Results 2WuXi PharmaTech Announces Third-Quarter 2011 Results 3WuXi PharmaTech Announces Third-Quarter 2011 Results 4WuXi PharmaTech Announces Third-Quarter 2011 Results 5WuXi PharmaTech Announces Third-Quarter 2011 Results 6WuXi PharmaTech Announces Third-Quarter 2011 Results 7WuXi PharmaTech Announces Third-Quarter 2011 Results 8WuXi PharmaTech Announces Third-Quarter 2011 Results 9WuXi PharmaTech Announces Third-Quarter 2011 Results 10WuXi PharmaTech Announces Third-Quarter 2011 Results 11WuXi PharmaTech Announces Third-Quarter 2011 Results 12WuXi PharmaTech Announces Third-Quarter 2011 Results 13WuXi PharmaTech Announces Third-Quarter 2011 Results 14WuXi PharmaTech Announces Third-Quarter 2011 Results 15WuXi PharmaTech Announces Third-Quarter 2011 Results 16WuXi PharmaTech Announces Third-Quarter 2011 Results 17WuXi PharmaTech Announces Third-Quarter 2011 Results 18GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 2GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 3GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 5
(Date:2/10/2015)... 2015  Alere Inc. (NYSE: ALR), a global ... for the quarter ended December 31, 2014. ... of Alere said, "We made substantial progress in ... global leader in rapid diagnostics and delivering against ... divestiture in early January enabled us to substantially ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... Science at the New York Academy of Sciences will ... "Frontiers in Agricultural Sustainability: Studying the Protein Supply Chain ... protein innovations in food science and programming that are ... protein to consumers worldwide. A full agenda can ...
... - 14 November 2013 The world should aim to ... are capable of eliminating malaria, licensed by 2030, according to ... new target comes in addition to the original 2006 Roadmap,s ... the most deadly form of the disease, for children under ...
... its recent research on the face biometrics market, ... the 2013 European Frost & Sullivan Award for ... biometrics earned the company strong domain expertise, which ... recognition technology, FaceVACS-VideoScan. FaceVACS-VideoScan analyses live ...
Cached Biology News:New malaria vaccines roadmap targets next generation products by 2030 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 3Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 4Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 5
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: